

4-Hydroxy-L-threonine, a Committed Precursor of Pyridoxol (Vitamin B₆)


Eckardt Wolf,^a Robert E. Hill,^b Brian G. Sayer^a and Ian D. Spenser*^{a†}

^a Department of Chemistry, McMaster University, Hamilton, Ontario L8S 4M1, Canada

^b Department of Pathology, McMaster University, Hamilton, Ontario L8N 4Z5, Canada

Having established in an earlier experiment that, in *Escherichia coli*, 4-hydroxy-L-threonine [(2*S*,3*S*)-2-amino-3,4-dihydroxybutanoic acid] lies on the route from glucose to vitamin B₆, it is now demonstrated that the amino acid serves as a precursor of pyridoxol, since ¹³C NMR spectroscopy shows that the intact C-2,3 bond of [2,3-¹³C₂]-4-hydroxy-L-threonine **2** becomes the C-5,6 bond of pyridoxol **1**.

It has been shown by tracer experiments with [1,2-¹⁴C]- and with [2-¹⁴C]-glycolaldehyde,^{1,2} and with [2-¹⁴C]- and with [2-¹³C,¹⁵N]-glycine,³ that, in *Escherichia coli*, C-5 and C-5' of pyridoxol **1** (unstarred) can be derived from the aldehyde and the carbinol carbon atom, respectively, of glycolaldehyde **3**, and that the N-1,C-6 fragment of the vitamin can be derived from the intact N,C-2 unit of glycine **4**. Based on these findings, we postulated⁴ that 4-hydroxy-L-threonine **2** (unstarred), originating from an aldol type condensation of glycine **4** with glycolaldehyde **3**, analogous to the formation of serine from glycine and formaldehyde,⁵ catalysed by glycine hydroxymethyltransferase (serine hydroxymethylase, EC 2.1.2.1), might be an intermediate in pyridoxol biosynthesis, to yield the C₃N unit, N-1,C-6,5,5' of the vitamin. Indirect evidence that 4-hydroxy-L-threonine is implicated in pyridoxine biosynthesis came from genetic⁶ and nutritional studies.⁷



The C₃ fragment in question, C-6,5,5' of pyridoxol, is also generated from an intact C₃ unit that is derived from glucose.⁸ We have recently demonstrated⁹ that the presence of 4-hydroxy-L-threonine [(2*S*,3*S*)-2-amino-3,4-dihydroxybutanoic acid] in the incubation medium totally inhibits incorporation of the label from [1,2,3,4,5,6-¹³C₆]glucose into C-6,5,5' of pyridoxol, whereas at the same time incorporation of the label




Fig. 1 125.776 MHz proton-decoupled ¹³C NMR spectrum of pyridoxol hydrochloride (in 50 μl D₂O, saturated solution) isolated from *E. coli* B WG2 after incubation with [2,3-¹³C₂]-4-hydroxy-L-threonine **2**. The spectrum was acquired on a Bruker AM 500 spectrometer. A 90° pulse width (6.4 μs) was used with a spectral width of 29411 Hz and a recycle time of 10.5 s. Initial memory size was 32 K which was zero-filled to 64 K before Fourier transformation to give a final digital resolution of 0.9 Hz per data point.

into the other five carbon atoms of pyridoxol remains unimpaired. Thus, 4-hydroxy-L-threonine lies on the pathway from glucose into the C₃ fragment C-6,5,5' of pyridoxol. Moreover, since 4-hydroxy-L-threonine totally inhibits incorporation of a glucose-derived C₃ fragment into C-6,5,5' of pyridoxol,⁹ it would appear that the amino acid serves as a feedback inhibitor of its own biosynthesis from D-glucose‡ and consequently of this segment of the biosynthetic pathway.

To provide final substantiation of the role of 4-hydroxy-L-threonine in the biosynthesis of vitamin B₆, that is, to show that the compound serves as a direct precursor of the C₃N unit N-1,C-6,5,5' of the vitamin, it must be demonstrated that the C₃N-unit, N,C-2,3,4 of the amino acid is incorporated, with its C-2–C-3 bond intact. We now present evidence, from an experiment with [2,3-¹³C₂]-4-hydroxy-L-threonine **2**, that this is indeed so.

Five 1 l cultures of *E. coli* B mutant WG2 were each incubated, with D-glucose (0.5 g) as the general carbon source, in the presence of [2,3-¹³C₂]-4-hydroxy-L-threonine **2**§ (160 mg) and L-threonine (20 mg l⁻¹). 4-Hydroxy-L-threonine partially inhibits the growth of *E. coli* B on a pyridoxal supplemented growth medium¹⁰ but addition of L-threonine permits the mutant to grow. Pyridoxol hydrochloride was isolated¹¹ from each 1 l culture after addition of pyridoxol hydrochloride (2.5 mg) as carrier, and was purified by column and thin layer chromatography. The samples were combined and the product purified by sublimation in a high vacuum.

The proton-decoupled 125.7 MHz ¹³C NMR spectrum of the sample of pyridoxol **1** hydrochloride so obtained is shown in Fig. 1. Each of the two signals, due to C-5 (δ 138.8) (¹J_{5,6} 64.6 ± 0.2 Hz) and C-6 (δ 131.8) (¹J_{5,6} 64.6 ± 0.2 Hz), appears as a doublet, straddling the natural abundance singlet originating from the carrier pyridoxol that had been added to facilitate isolation. Thus, the labelled bond, C-2–C-3 of the precursor **2** had been incorporated intact into the C-6–C-5 bond of pyridoxol **1**. The signals due to the other six carbon atoms appear as natural abundance singlets. Incorporation had been site specific. This finding supplies the missing link in the evidence that 4-hydroxy-L-threonine, originating either from glucose^{6,8,9} or from glycine³ plus glycolaldehyde,^{1,2} serves as direct precursor of the C₃N unit N-1,C-6,5,5' of vitamin B₆.

A research grant from the National Institute of General Medical Sciences, US Public Health Service (Grant GM 50778, to I. D. S) is gratefully acknowledged. We thank Richard M. Pauloski for skilled technical assistance.


Received, 4th April 1995; Com. 5/02146D

Footnotes

† E-mail: spenser@mcmil.CIS.McMaster.CA

‡ Evidence from genetic studies⁶ with pyridoxine-requiring mutants of *Escherichia coli* suggests that the route from glucose into 4-hydroxy-L-threonine proceeds by way of the pentose phosphate pathway and that erythrose 4-phosphate, erythronic acid 4-phosphate and the corresponding α-keto acid are intermediates between glucose and the amino acid.

§ [2,3-¹³C₂]-4-Hydroxy-L-threonine **2** was synthesised from [1,2-¹³C₂]acetylene in 8 steps (Scheme 1), in an overall yield of 13%. A full account of the synthesis has been submitted for publication.



References

- 1 R. E. Hill, P. Horsewood, I. D. Spenser and Y. Tani, *J. Chem. Soc., Perkin Trans. 1*, 1975, 1622.
- 2 G. J. Vella, R. E. Hill, B. S. Mootoo and I. D. Spenser, *J. Biol. Chem.*, 1980, **255**, 3042.
- 3 A. Iwanow, R. E. Hill, B. G. Sayer and I. D. Spenser, *J. Am. Chem. Soc.*, 1984, **106**, 1840.
- 4 R. E. Hill and I. D. Spenser, in *Vitamin B₆, Pyridoxal Phosphate; Chemical, Biochemical and Medical Aspects, Part A*, ed. D. Dolphin, R. Poulson and O. Avramovic, Wiley, New York, 1986, pp. 417–476.
- 5 P. M. Jordan and M. Akhtar, *Biochem. J.*, 1970, **116**, 277.
- 6 H.-M. Lam and M. E. Winkler, *J. Bacteriol.*, 1990, **172**, 6518.
- 7 C. D. Drewke, C. Notheis, U. Hansen, E. Leistner, T. Hemscheidt, R. E. Hill and I. D. Spenser, *FEBS Lett.*, 1993, **318**, 125.
- 8 R. E. Hill, B. G. Sayer and I. D. Spenser, *J. Chem. Soc., Chem. Commun.*, 1986, 612.
- 9 I. A. Kennedy, R. E. Hill, R. M. Pauloski, B. G. Sayer and I. D. Spenser, *J. Am. Chem. Soc.*, 1995, **117**, 1661.
- 10 J. W. Westley, D. L. Pruess, L. A. Volpe, T. C. Demny and A. Stempel, *J. Antibiot.*, 1971, **24**, 330.
- 11 R. E. Hill, F. J. Rowell, R. N. Gupta and I. D. Spenser, *J. Biol. Chem.*, 1972, **247**, 1869.